ROE của cổ phiếu AQST là bao nhiêu?

AQUESTIVE THERAPEUTICS INC có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 202.36%.

Tỷ suất cổ tức của AQST là bao nhiêu?

AQUESTIVE THERAPEUTICS INC có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của AQST là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của AQST ở mức 54/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu AQST không?

Điểm AI Timing của AQST là 26/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu AQST thuộc ngành nào?

AQUESTIVE THERAPEUTICS INC được xếp vào ngành Healthcare >> Drug Manufacturers - Specialty & Generic trên sàn NASDAQ

Cổ phiếu AQST (NASDAQ) | AQUESTIVE THERAPEUTICS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

AQST AI Analysis Summary

Our AI summary for AQST: AQUESTIVE THERAPEUTICS INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.00, ROE of 202.36%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

AQST

AQUESTIVE THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Drug Manufacturers - Specialty & Generic

USD 3.70

-0.03 (-0.67%) Day Change

Watchlist Portfolio Compare Chart

-1.19

D/E

202.4%

ROE

-48.8%

ROA

0.00%

Div Yield

AQUESTIVE THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 3.70 Price -0.03 (-0.67%) Day Change	NEWS SCORE: N/A

AQST Chất lượng tổng thể của cố phiếu Không tốt lắm ( Chất lượng = 54) và Thời điểm mua ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ ROA tương đối thấp
ROE đang giảm đáng kể
ROA quá thấp so với ROE
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

51%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	3.70
PBV / Sector	-13.71 / 3.22
Earning Per Share	-0.55

PE / Sector	N/A / 29.79
PEG or PE/Growth / Sector	N/A / 0.13
Average 1M Daily Value	7.23 M
Average 1W Daily Value	7.69 M

Yếu tố Kỹ thuật

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-137.08 / 15.21
NPM Average (%) / Sector	-106.30 / -10.83
NPM Change Average (%) / Sector	106.16 / 117.42 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-48.83 / 8.15
ROA Average (%) / Sector	-50.72 / 2.87
ROA Change Average (%) / Sector	36.34 / 112.70 GREAT
ROE (%) / Sector	202.36 / -1.02 GREAT
ROE Average (%) / Sector	115.58 / 8.35 GREAT
ROE Change Average (%) / Sector	257.35 / 385.91 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Chi tiết đăng ký

Analyze Date	2026-08-01 07:59:29
Symbol	AQST
Name	AQUESTIVE THERAPEUTICS INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	125.47 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	466.74 / 10,754.62

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 30 Technology Drive, Warren, NJ, United States, 07059

Phone: 908 941 1900

Website: https://www.aquestive.com

Employees: 147

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.